


# UNIVERSAL IBOGAINE

Creating The  
Gold Standard For  
Addiction Treatment



UNIVERSAL  
IBOGAINE™

TSX-V: IBO



TSX-V: IBO


## DISCLAIMER AND USE OF FORWARD-LOOKING STATEMENTS

This presentation is provided for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided solely to assist the recipient in evaluating Universal Ibogaine Inc. ("UI" or the "Company"). The presentation is not, nor is it construed under any circumstances as a prospectus, a public offering of securities, or an offering memorandum as defined under any applicable securities legislation, as it does not contain all of the information that would normally appear in an offering registered under applicable securities laws. The information contained herein is subject to change without notice and is based on publicly available information, internally developed information and other sources. Where any opinion or belief is expressed herein, it is based on assumptions and limitations mentioned and is an expression of current opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature, arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or reason of reliance on it by any person. This presentation should not be construed as legal, financial or tax advice, as each individual's circumstances are different, and readers should consult with their own professional advisors. The information contained in this presentation is not directed to person or entities resident in the United States and does not constitute an offer or a solicitation by anyone in the United States ("U.S.") or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation.


ANY SECURITIES DESCRIBED IN THIS PRESENTATION HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATES OF THE U.S. THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE U.S. OR TO "U.S. PERSONS" AS SUCH TERM IS DEFINED IN THE REGULATIONS UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.

Certain statements contained or incorporated in this presentation, which deal with the financial condition and results of the Company, may include information, projections and analyses as to future developments which are currently in the planning stage and reflect the current expectations of UI management regarding future growth, results of operations, performance, business prospects and opportunities. Such forward-looking statements, including references to the Company's treatment protocol and medical research and developments efforts (including in-house and independent pre-clinical and clinical trial plans) involve known and unknown risks and uncertainties that could cause actual events and/or results to differ materially from those estimated and/or anticipated and which may have been implied and/or expressed in such forward-looking statements. No conclusions as to the successful outcome of UI's ongoing and planned R&D projects are intended or implied nor can they be foreseen or predicted prior to definitive corporate announcements as to their outcome. There is no assurance that UI will obtain projected revenues or income related to ibogaine as these are subject to obtaining regulatory approvals to use ibogaine which requires successful conclusion of clinical trials and subsequent approvals by necessary regulatory and legal agencies in each country the company plans to operate which are inherently uncertain and subject to the uncertainties of clinical trials or the acceptance of the results by regulatory agencies. Opening additional clinics will require additional financing which may not be available to the company.

## UNIVERSAL IBOGAINE MISSION



We aim to provide those living with addiction with an improved treatment toward better outcomes by developing and applying a state-of-the-art, comprehensive and holistic, care model, while introducing ibogaine as a central piece of the solution set.



## INVESTMENT THESIS

1. Universal Ibogaine offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically-supervised and regulatory-sanctioned channel to participate in the PSYCHEDELICS space.
2. Our ibogaine “biotech” play is inherently “de-risked” due to the real-world data/evidence base of safety and efficacy, and the successful track record of our Clear Sky Recovery treatment/safety protocol.
3. We represent a commercialization and monetization opportunity in a large, severely underserved, therapeutic area: Addiction, mental/behavioral health and overall nervous system (CNS) disorders.
4. We present an opportunity to capture a biotech upside while growing near-term revenue from expansion of clinics.
5. Our valuation is favorable compared with companies in the (psychedelic) space as we are at the ground level, at a pre-transformative growth stage.






## OUR FOUNDING STORY



TSX-V: IBO



### MEETING

Universal Ibogaine was born in 2018: Canadian financier Shayne Nyquvest met Dr. Alberto Sola, the world's most experienced ibogaine treatment provider, at his clinic in Cancun (Mexico).

### CLEAR SKY

Dr. Sola's ibogaine treatment protocol has disrupted addiction by safely administering over 3,700 treatments to patients since 2007.

### UNIVERSAL IBOGAINE



Was created with the goal of medicalizing ibogaine for addiction treatment in Canada and then globally.

## PROGRESS TO DATE

- Public listing on the TSX Venture Exchange in September 2021\* through amalgamation with P Squared Renewables – A Capital Pool Company
- Raised \$6M to support ibogaine clinical development and addiction clinics rollout
- Arranging for clinical trials to medicalize ibogaine in Canada, including securing contract research organizations (CROs), drug supply, and institutional partners
- Acquired the revenue-generating Kelburn Addiction Recovery Center practice (Manitoba), along with property consisting of 50 acres of land
- Expanded the senior leadership team and Board of Directors
- Acquired the exclusive worldwide rights for the Clear Sky Proprietary Treatment and Safety Protocol, and the Clear Sky brand
- Acquired land in the Caribbean (Belize) with an eye toward co-development of an addiction aftercare treatment center
- Established strategic relationships with indigenous leadership focused on addiction

*\*Pending final approval by the exchange.*

TSX-V: IBO



TSX-V: IBO

## OUR LEADERSHIP TEAM



### Dr. Rami Batal, PharmD/PhD – Chief Executive Officer

Dr. Rami Batal is a seasoned biopharmaceutical industry executive and a healthcare professional who has a passion for, and expertise and experience in, neuropsychiatry and mental health/behavioral health illnesses, including substance use disorders. Dr. Batal has occupied leadership and influencing roles in research and development, strategic marketing and business development at Antibe Therapeutics, Canopy Growth, Beckley-Canopy (now Beckly-Psytech), Purdue Canada, and Yumanity Therapeutics. Dr. Batal holds a doctorate in Experimental Medicine from McGill, and an MBA from Concordia. He is a Canada Board certified Pharmacist, and is licensed to practice.

### Greg Leavens, CPA – Chief Financial Officer

Greg Leavens, CPA CA - is a financial executive, CFO and Controller with 30 years of experience in public accounting and industry, including the oil & gas exploration / production and service sectors. Greg started his career with KPMG, and has extensive experience in leadership, strategic planning, due diligence reviews, financing, forecasting, financial reporting, treasury and risk management, and regulatory compliance.



### Dr. Glenn Copeland – Senior Medical Advisor

Dr. Copeland is internationally recognized for his work as the former founder, chairman and CEO of the renowned Cleveland Clinic Canada. He also established the Rehab and Wellbeing Centre and Sports Medicine Centre at Mount Sinai Hospital in Toronto.



## EXECUTIVE (OPERATING) BOARD OF DIRECTORS



### Chief Ian Campbell, MBA – Chairman (*Independent*)

Chief Ian Campbell (Xalek) is a hereditary chief of the Squamish Nation located in Vancouver, British Columbia. He has served as an elected member of council since 2005, and was appointed as a Political Spokesperson in 2008. Since 1999 he has been the Cultural Ambassador and Negotiator for the Intergovernmental Relations Department of the Squamish Nation, advancing Aboriginal rights and title, while invigorating substantive economic opportunities through negotiations, collaboration, and partnerships.

Ian graduated from Simon Fraser University with an MBA in Aboriginal Business and Leadership.

### Alberto Sola, MD - Co-Founder and Director

Clear Sky Addiction Solution's President, Dr. Sola is a thought leader in entheogenic treatment. He has the distinction of having treated more patients with ibogaine than any other person in the world and is head of operations at Clear Sky Recovery. Dr. Sola graduated from Universidad Anahuac. As the Medical Director of Amerimed, he opened four emergency hospitals for tourists in Puerto Vallarta, Cancun, and Cabo San Lucas.





## EXECUTIVE (OPERATING) BOARD OF DIRECTORS

### Robert Turner, ICD.D, MBA – Director (*Independent*)



Mr. Turner is President of his own incorporated consulting firm and a Principal within Western Management Consultants. His consulting focus is providing guidance to boards on their governance including proper CEO oversight. Mr. Turner brings experience as a CHRO in both the private and public sectors. Subsequently, he joined Mercer Canada as a Partner focused on consulting within Canadian health care.

Robert has served on Universal Ibogaine's Advisory Board since December 2018. Robert has an ICD.D certification from Rotman Business School, an MBA from the Ivey Business School and a BSc (Biochemistry) from the University of Toronto. He serves on the Boards of two other corporations – one private and one not-for-profit.

### Marilyn Loewen Mauritz, ICD.D, JD – Director (*Independent*)

Marilyn Loewen Mauritz is a senior corporate executive with over 25 years of experience in diverse industries. From 2015 to January 2021, Ms. Mauritz held several senior executive positions at Central 1 Credit Union, a leading provider of financial, digital banking and payment solutions, including serving as the interim Chief Executive Officer. Most recently, she served as Central 1's Chief Transformation & Legal Officer, where she led the Legal, Compliance, Governance, Strategy, Information Technology and Government Relations teams.

Prior to joining Central 1, she was General Counsel and Corporate Secretary at Interfor Corporation. She currently serves on the Board of YWCA of Greater Vancouver, chairing the Governance and Nominating Committee.

Marilyn obtained her Bachelor of Law degree from the University of Calgary and holds a Bachelor of Arts degree from McMaster University. She is a graduate of the Institute of Corporate Directors, ICD.D.





## PLANNED TEAM EXPANSION

### 2021



- Chief Medical Officer; Chief Clinics Officer; Vice-President Drug Development
- Board Members:
  - Capital Markets; Finance/Audit (CPA)

### 2022

- Medical and Scientific Advisory Board
- Business Advisory Board



# ADDICTION AND IBOGAINE



TSX-V: IBO

TSX-V: IBO



## ADDICTION FIGURES AND FACTS

- On average every 2 hours, a death occurs in Canada due to illicit drug overdose\*.
- Addiction is closely intertwined with mental/behavioral health and CNS – All subject to an increasing societal and industrial focus.
- Current addiction management, although a good start, is in many cases inadequate: recidivism (relapse) rate is >90%\*.
- Addiction is addressed primarily as an acute, singular, condition. There is a strong case for multi-faceted, chronic, disease management approaches.
- There is increased reliance in addiction management on “substitution therapy” whereby, for example, another opioid is introduced as a long-term treatment for opioid use disorder.
- “Harm reduction” practices are becoming increasingly popular: they might save lives. However, they don’t blunt addiction or address its underlying causes.

**New approaches and innovation in long-term addiction care are required: ibogaine, in association with other modalities, would work differently from current addiction medicines.**

\*Sources: <https://www.cbc.ca/news/canada/british-columbia/overdose-crisis-bc-public-health-agency-canada-report-1.4902884>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855417/>




**Addressable Market**

• 1-In-5 •

Canadians Live With Addiction Each Year

UNIVERSAL IBOGAINE




“If we’re just substituting one opioid for another, we’re not moving the dial much”

Tom Price, Former U.S. Secretary of HHS

TSX-V: IBO

## IBOGAINE: A MEDICAL PSYCHEDELIC FOR ADDICTION

TSX-V: IBO



- Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants.
- Potent and serious medical psychedelic which evidence demonstrates has addiction-interrupting properties
- Broad spectrum (promiscuous) agonizer: targets multiple receptors across multiple sites in the brain
- Metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings
- Has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization

Universal Ibogaine will develop and medically introduce ibogaine as a central piece in addiction treatment.





TSX-V: IBO

THE PLAN





TSX-V: IBO



14

TO TRANSFORM ADDICTION MANAGEMENT, WHILE DEVELOPING IBOGAINE AS A CENTRAL COMPONENT OF INNOVATIVE ADDICTION TREATMENT



*\*Introduction of ibogaine and other medical psychedelics will be subject to legal and regulatory authorization in respective jurisdictions.*


TSX-V: IBO

1

## DRUG (IBOGAINE) DEVELOPMENT PROGRAM: IMPETUS

- We are pursuing a Health Canada approval to conduct a clinical trial to demonstrate the safety and efficacy of ibogaine in treating opioid use disorder.
- The study is intended to ultimately lead to the medical use of ibogaine in Canada, and to support similar endeavours in other G7 countries.
- The study will be led by a strong medical team, potentially with institutional support, and will be facilitated by experienced Clinical Research Organizations.
- Successful ibogaine development affords us eight-year data exclusivity protection for innovative medicines in Canada, and opens doors for future drug development and intellectual property generation related to ibogaine and other technologies.

Operating in Canada comes with added advantages: i) receptivity to medical psychedelics, ii) research cost effectiveness and acceleration, iii) research harmonization, and iv) ibogaine prescription drug list status (mentioned earlier).




TSX-V: IBO

1

## DRUG (IBOGAINE) DEVELOPMENT PROGRAM: CLEAR SKY TREATMENT PROTOCOL



- Universal Ibogaine has acquired treatment/safety protocol (worldwide) rights from Clear Sky Recovery in Cancun (Mexico), along with patient safety data and the Clear Sky Recovery Solution brand.
- The Clear Sky treatment/safety protocol and real-world patient data (>3,700 treatments to date: more patients treated safely than anywhere else in the world) will inform the Phase 2 study.
- The Clear Sky treatment/safety protocol may also inform ibogaine medicalized introduction in Canada.

TSX-V: IBO



1

## DRUG (IBOGAINE) DEVELOPMENT PROGRAM: PROJECTED ROADMAP





*\*Human proof of concept study [usually aligned with a ph2B (phase 2) development stage]*

TSX-V: IBO



1


## DRUG (IBOGAINE) DEVELOPMENT PROGRAM: ADVANCEMENT SCENARIOS



\*Acronyms: NOL = No Objection Letter (from Health Canada); NOC = Notice of Compliance (from Health Canada)

\*\*Special access status is a less traditional route to market introduction, requiring Health Canada's consent (granted for some other psychedelics).

TSX-V: IBO



2

## ADDICTION CLINCS: FIRST STEP KELBURN




- Kelburn (greater Winnipeg, MB) rehab center acquired, along with 50 acres
- Kelburn is revenue generating with substantial growth opportunities:
  - Development of detox center
  - Introduction of “novo treatments”, including psychedelics as authorized
  - Base/residential (including informatics-enabled) aftercare modalities
  - Development of a state-of-the-art comprehensive and holistic addiction management care model, to be rolled out to future Universal Ibogaine clinics (in Canada, US, internationally), and to be further monetized by offering training and franchising
  - Opportunity for academic research collaborations (research park) with the University of Manitoba, also a model for future collaborations elsewhere
- Kelburn will also support the drug (ibogaine) development program.

2

## ADDICTION CLINICS MILESTONES

TSX-V: IBO



--2021--

Q4

Q1

Q2

--2022--

Q3

Q4 (Onward)



Kelburn Optimized



Clinic acquisition targets identified



"Corporate" Clinic 2 Acquired



"Corporate" Clinics 3+ Acquired (Canada / US)



Addiction Management Model Finalized




Certified Training / Managed Franchising Rollout



International (ex-US) Exploration and Expansion

TSX-V: IBO

## TSX-V: IBO



## 3


- Collaboration opportunities related to indigenous holistic medicine, particularly the utility of medical psychedelics / ibogaine, as well as outpatient / in-community care and aftercare
- Exploration of legal/regulated options for a “parallel” (post HPOC/Ph2 clinical study and while working with Health Canada) path for ibogaine and other medical psychedelics targeting addiction and co-morbidities within indigenous lands

## 4


- Exploration of ibogaine and other medical psychedelic treatments for addiction in potentially permissible jurisdictions (e.g., Bahamas, Belize, Cancun)
- Exploration of developing a continuum of care / patient referral system
- *All above subject to legal considerations and regulatory approval*



## KEY, NEAR-TERM, MILESTONES



\*Acronyms: CTA = clinical trial application; MOU = Memorandum of Understanding






TSX-V: IBO





FINANCIAL CONSIDERATIONS






## REVENUE AND VALUATION POTENTIAL

- **POTENTIAL REVENUE SOURCES:** i) clinics (direct operation = “corporate clinics”; certified training/licensing/franchising); ii) patient referral or direct operation in the Caribbean where and when authorized; iii) operation on indigenous lands where and when appropriate; iv) accelerated medicalization/commercialization of ibogaine post completion of the HPOC/Ph2 study; and v) monetization of other addiction medicine / technology, etc.
- **VALUATION DRIVERS:** i) cash flow (as articulated above); ii) leading presence in the addiction therapy area; iii) drug(s) development program milestone achievements; and iv) goodwill/intangibles: brands (starting with Clear Sky Recovery brand), advancement with the indigenous community, Caribbean establishment of operation and infrastructure expansion, intellectual property/exclusivity generation and protection, etc.

Year	Revenue Potential*	Valuation Potential*
2021 ( <u>annualized</u> )	\$2M	\$50-75M
2022	\$20M	\$200M
2023	>\$50M	\$500M
2024	>\$100M	>\$1B

*\*Preliminary estimates based on a rudimentary business trajectory; they do not constitute projections or guidance*

## COMPARABLE VALUATIONS\*




\*Source: <http://ca.finance.yahoo.com/> (early September 2021 readout)

TSX-V: IBO


TSX-V: IBO

## USE OF RAISED PROCEEDS



Intended use of net proceeds	\$ millions
Closing of acquisition of Manitoba clinic (including closing costs)	0.5
Clinical development program	1.8
Repayment of promissory notes (if not converted)	0.4
Working capital (for G&A etc.)	2.9
Estimated net proceeds	5.6

The Company's \$6 million Subscription Receipt Financing of \$0.25 Units closed on August 31, 2021.



## CAPITAL STRUCTURE (POST RAISE)

<i>in # millions</i>		UI	PSQ	Post RTO Total
Shares issued and outstanding	note 1)	131.4	12.1	143.5
Issued on UI RTO Liquidity Event under 2018 financing		13.2		13.2
Issued on closing of \$6 million Subscription Receipt Financing			24.0	24.0
Acquisition of Kelburn Clinic (Manitoba)		9.6		9.6
Totals at Amalgamation on August 31, 2021		154.2	36.1	190.3

### Notes:

1) includes 30 million shares issued to Clear Sky,  
90% of which will be subject to future performance milestones.



## CAPITAL STRUCTURE (POST RAISE): RESERVED FOR ISSUE

<i>in # millions</i>	exercise price	post RTO term	UI	PSQ	Post RTO Total
Options (brokers and PSQ Directors)	\$0.10	1 to 2 years	3.8	1.1	4.9
Options (UI D&Os)	\$0.25	5 years	6.7		6.7
Performance shares - Directors and CEO (based on clinical trials and other targets)	n/a	n/a	3.7	-	3.7
Advisors warrants	\$0.25	Dec 31, 2024	9.0	-	9.0
Warrants issued with the \$0.25 share Units	note 1)	5 years	17.9	24.0	41.9
Warrants issued on acquisition of Kelburn Clinic	note 1)	5 years	9.5		9.5
Pro Forma total			50.6	25.1	75.7

## Notes:

1) exercise price of \$0.50 in year 1, escalating by \$0.25 per year to \$1.50 if exercised in year 5.



# Freedom From Addiction Is Possible



[www.Universallbogaine.com](http://www.Universallbogaine.com)

TSX-V: IBO

[Rami.Batal@Universallbogaine.com](mailto:Rami.Batal@Universallbogaine.com)

September 2021